BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakatake M, Kurosaki H, Kuwano N, Horita K, Ito M, Kono H, Okamura T, Hasegawa K, Yasutomi Y, Nakamura T. Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function. Mol Ther Oncolytics 2019;14:159-71. [PMID: 31236440 DOI: 10.1016/j.omto.2019.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Zeng J, Li X, Sander M, Zhang H, Yan G, Lin Y. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Front Immunol 2021;12:721830. [PMID: 34675919 DOI: 10.3389/fimmu.2021.721830] [Reference Citation Analysis]
2 Yamashita M, Tasaki M, Murakami R, Arai Y, Nakamura T, Nakao S. Oncolytic vaccinia virus induces a novel phenotype of CD8+ effector T cells characterized by high ICOS expression. Mol Ther Oncolytics 2021;20:422-32. [PMID: 33665362 DOI: 10.1016/j.omto.2021.01.016] [Reference Citation Analysis]
3 Kurosaki H, Nakatake M, Sakamoto T, Kuwano N, Yamane M, Ishii K, Fujiwara Y, Nakamura T. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice. Cells 2021;10:985. [PMID: 33922406 DOI: 10.3390/cells10050985] [Reference Citation Analysis]
4 Bhatt DK, Chammas R, Daemen T. Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis. Vaccines (Basel) 2021;9:1166. [PMID: 34696274 DOI: 10.3390/vaccines9101166] [Reference Citation Analysis]
5 Nakatake M, Kuwano N, Kaitsurumaru E, Kurosaki H, Nakamura T. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment. Mol Ther 2021;29:1782-93. [PMID: 33348052 DOI: 10.1016/j.ymthe.2020.12.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Shin J, Hong SO, Kim M, Lee H, Choi H, Kim J, Hong J, Kang H, Lee E, Lee S, Kong B, Kim M, Choi H, Kim S. Generation of a Novel Oncolytic Vaccinia Virus Using the IHD-W Strain. Hum Gene Ther 2021;32:517-27. [PMID: 32854548 DOI: 10.1089/hum.2020.050] [Reference Citation Analysis]
7 Matsugo H, Kitamura-Kobayashi T, Kamiki H, Ishida H, Sekine W, Takenaka-Uema A, Nakagawa T, Murakami S, Horimoto T. A potential bat adenovirus-based oncolytic virus targeting canine cancers. Sci Rep 2021;11:16706. [PMID: 34408176 DOI: 10.1038/s41598-021-96101-4] [Reference Citation Analysis]
8 Zhang Z, Dong L, Zhao C, Zheng P, Zhang X, Xu J. Vaccinia virus-based vector against infectious diseases and tumors. Hum Vaccin Immunother 2021;17:1578-85. [PMID: 33606578 DOI: 10.1080/21645515.2020.1840887] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Wu TM, Liu JB, Liu Y, Shi Y, Li W, Wang GR, Ma YS, Fu D. Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control. Cancer Control 2020;27:1073274820934805. [PMID: 32806937 DOI: 10.1177/1073274820934805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kaygisiz K, Synatschke CV. Materials promoting viral gene delivery. Biomater Sci 2020;8:6113-56. [PMID: 33025967 DOI: 10.1039/d0bm01367f] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]